Last reviewed · How we verify
Gemcitabine, Cisplatin, Sunitinib
Gemcitabine is a nucleoside analog that inhibits DNA synthesis by inhibiting ribonucleotide reductase.
Gemcitabine is a nucleoside analog that inhibits DNA synthesis by inhibiting ribonucleotide reductase. Used for Non-small cell lung cancer, Pancreatic cancer, Breast cancer.
At a glance
| Generic name | Gemcitabine, Cisplatin, Sunitinib |
|---|---|
| Also known as | Gemzar, Sutent |
| Sponsor | US Oncology Research |
| Drug class | Nucleoside analog |
| Target | Ribonucleotide reductase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Gemcitabine is a chemotherapy medication used to treat various types of cancer. It works by inhibiting DNA synthesis, which ultimately leads to cell death.
Approved indications
- Non-small cell lung cancer
- Pancreatic cancer
- Breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
- Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) (PHASE2)
- Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) (PHASE2)
- Gemzar, Cisp, Sunitinib Urothelial Ca (PHASE2)
- Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma (PHASE1)
- Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC (PHASE2)
- Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine, Cisplatin, Sunitinib CI brief — competitive landscape report
- Gemcitabine, Cisplatin, Sunitinib updates RSS · CI watch RSS
- US Oncology Research portfolio CI